Contents

Diabetes MellitusEdit

Diabetes mellitus is a group of chronic metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Persistent high blood glucose damages organs over time and raises the risk of a range of complications affecting the eyes, kidneys, nerves, heart, and blood vessels. The term covers several subtypes, with the most common being Type 1 diabetes mellitus, Type 2 diabetes mellitus, and gestational diabetes mellitus. Less common forms include maturity-onset diabetes of the young (MODY) and latent autoimmune diabetes in adults (LADA). For context, see Diabetes mellitus and related topics such as insulin, glucose, and pancreas.

Diabetes mellitus in its various forms is a major global health issue, with prevalence rising in many regions alongside aging populations and rising rates of overweight and obesity. Management focuses on maintaining blood glucose levels in a range that minimizes symptoms and complications, while supporting overall health through lifestyle measures, regular monitoring, and appropriate medication.

Overview and pathophysiology

Diabetes arises when the body cannot regulate blood glucose effectively. Normal glucose homeostasis relies on adequate insulin production by pancreatic beta cells and effective insulin action on target tissues. In Type 1 diabetes, autoimmune processes destroy beta cells, reducing or eliminating insulin production. In Type 2 diabetes, insulin resistance in tissues coupled with progressive beta-cell dysfunction leads to rising blood glucose over time. Gestational diabetes results from pregnancy-related hormonal changes that increase insulin resistance, typically resolving after delivery but conferring higher long-term risk for both mother and child.

Key biological players include insulin, the hormone that lowers blood glucose; the pancreas, the organ containing beta cells; and various tissues such as muscle and liver where glucose uptake and production are regulated. Ongoing research also explores cellular and molecular mechanisms underlying beta-cell stress, insulin signaling, and the role of inflammation in metabolic disease.

Major forms

Type 1 diabetes mellitus

Type 1 diabetes is predominantly autoimmune in nature, with immune-mediated destruction of pancreatic beta cells. It typically presents in childhood or young adulthood but can occur at any age. Individuals with Type 1 diabetes require exogenous insulin to survive. Acute risk includes diabetic ketoacidosis (DKA), a life-threatening state of insulin deficiency that demands prompt treatment. See Type 1 diabetes mellitus for more details.

Type 2 diabetes mellitus

Type 2 diabetes is characterized by insulin resistance and a progressive decline in beta-cell function. It is strongly associated with obesity, physical inactivity, and family history, and it is more common in adults but increasingly seen in younger people. Management emphasizes glycemic control through lifestyle changes and medications that may delay or reduce complications. See Type 2 diabetes mellitus.

Gestational diabetes mellitus

Gestational diabetes occurs when pregnancy-induced hormonal changes worsen insulin resistance. It affects an estimated proportion of pregnancies worldwide and is associated with risks to both mother and fetus, including larger birth weight and future risk of developing type 2 diabetes. See Gestational diabetes.

Other forms

  • Latent autoimmune diabetes in adults (LADA) shares features with both Type 1 and Type 2 diabetes, including slower progression and autoimmunity. See Latent autoimmune diabetes in adults.
  • Maturity-onset diabetes of the young (MODY) refers to several hereditary forms of diabetes that occur at a younger age and have characteristic genetic causes. See Maturity-onset diabetes of the young.

Epidemiology and risk factors

Diabetes affects hundreds of millions of people worldwide. Risk factors span genetics, body weight, diet, physical activity, and socioeconomic determinants of health. While prevalence varies by region, risk is higher in populations with higher rates of obesity and sedentary lifestyles, and disparities in access to care contribute to differences in outcomes. See epidemiology for broader context and related terms such as cardiovascular disease and nephropathy.

Signs, symptoms, and screening

Common symptoms across many forms include excessive thirst (polydipsia), frequent urination (polyuria), unintended weight loss, fatigue, and blurred vision. Some individuals, particularly those with Type 2 diabetes or gestational diabetes, may not have noticeable symptoms initially, making screening important in at-risk groups. Screening guidelines vary by country and health system but commonly involve measurements of fasting glucose, oral glucose tolerance tests, and/or HbA1c levels. See hyperglycemia and hypoglycemia for related concepts.

Diagnosis

Diagnosis relies on measurements of blood glucose and glycemic control: - Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) - 2-hour plasma glucose after an oral glucose tolerance test (OGTT) ≥ 200 mg/dL (11.1 mmol/L) - A1c (glycated hemoglobin) ≥ 6.5% on two occasions - In the presence of classic hyperglycemia symptoms, a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) may suffice These criteria are used with consideration of clinical context and may be updated as guidelines evolve. See HbA1c and fasting plasma glucose.

Management

Lifestyle and prevention

Lifestyle modification—weight management, balanced nutrition, and regular physical activity—remains foundational for most patients with Type 2 diabetes and can reduce the risk of progression in those with prediabetes. Education about healthy eating patterns and portion control, as well as programs that support physical activity, are commonly part of comprehensive care. See lifestyle modification.

Pharmacologic therapy

  • Type 1 diabetes: lifelong insulin therapy is essential. Treatment regimens use different insulin types and delivery methods, tailored to the individual.
  • Type 2 diabetes: initial therapy often includes metformin, with escalation to additional medications as needed. Classes include SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and others, depending on patient factors such as kidney function, cardiovascular risk, and weight. In some patients, insulin therapy becomes necessary. See metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin.
  • Gestational diabetes: management balances maternal and fetal safety, commonly starting with dietary modification and physical activity; pharmacologic therapy (often insulin) is used if glucose targets are not met. See gestational diabetes.

Monitoring and self-management

  • Self-monitoring of blood glucose (SMBG) helps patients adjust treatment and behavior.
  • Continuous glucose monitoring (CGM) provides near real-time glucose data and can improve control for many patients.
  • Regular monitoring of blood pressure, lipids, kidney function, and eye health is part of comprehensive care.
  • Vaccinations (e.g., influenza and pneumococcal vaccines) are recommended to reduce infection risk. See self-monitoring of blood glucose and continuous glucose monitor.

Complications and their prevention

Long-term hyperglycemia increases the risk of microvascular complications such as retinopathy, nephropathy, and neuropathy as well as macrovascular disease like coronary artery disease. Early and sustained glycemic control, blood pressure and lipid management, smoking cessation, and routine screening for complications reduce risk. See diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy.

Complications

  • Microvascular: retinopathy (eye disease), nephropathy (kidney disease), neuropathy (nerve damage). These can progress silently and require regular screening with eye examinations and kidney function tests.
  • Macrovascular: atherosclerotic cardiovascular disease, including heart attack and stroke, remains a leading cause of morbidity and mortality in diabetes.
  • Acute emergencies: diabetic ketoacidosis (DKA) more commonly in Type 1, and hyperosmolar hyperglycemic state (HHS) more common in older patients with Type 2, require urgent medical attention. See diabetic ketoacidosis and hyperosmolar hyperglycemic state.

Public health, disparities, and policy considerations

Diabetes imposes substantial economic and societal costs, including medical care, lost productivity, and disability, particularly where access to affordable care and medications is limited. Public health strategies emphasize early detection, lifestyle interventions, and appropriate allocation of resources to reduce preventable complications. Disparities in outcomes across racial, ethnic, and socioeconomic groups are an area of ongoing focus, with attention to how social determinants of health influence risk and access to care. See public health and health disparities.

Drug pricing and access to essential therapies, including insulin and modern glucose-lowering medications, are common topics of debate in many health systems. Balancing incentives for innovation with affordability remains a central issue in policy discussions around diabetes care. See drug pricing and health policy.

Research and future directions

Advances in diabetes research pursue improved prevention, earlier detection, and more precise treatment. Areas of active development include: - Islet cell replacement and transplantation strategies, potentially reducing or eliminating the need for exogenous insulin in some patients. See islet cell transplantation. - Closed-loop (artificial pancreas) systems that combine CGM data with automated insulin delivery to maintain glucose in target ranges. - New drug classes and combination therapies that address cardiovascular risk, weight management, and renal protection. See artificial pancreas and cardiovascular risk.

Controversies and debates

Ongoing debates touch on access to care, the high cost of newer therapies, and the most effective strategies for population health: - How to balance innovation with affordability: proponents of strong patent protection argue it drives new treatments, while opponents warn high prices limit access and worsen outcomes for some patients. - Public vs private health coverage: discussions about whether government programs should cover comprehensive diabetes care and medications, or whether private insurance and market competition are more efficient at delivering care. - Screening and prevention strategies: debates exist about the best age to begin screening, the role of lifestyle interventions in prevention, and the allocation of resources between prevention and acute treatment. - Technology adoption: CGMs and digital health tools can improve control but raise questions about costs, data privacy, and equal access across populations.

In these debates, it is common to see a spectrum of viewpoints that emphasize personal responsibility and market-driven solutions on one side, and broader public health approaches and collective funding on the other. See health policy and diabetes care for related discussions.

See also